• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login

    Investing News NetworkYour trusted source for investing success

    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Biotech Market
    Biotech News
    Biotech Stocks
    • Biotech Market
    • Biotech News
    • Biotech Stocks

    Cystic Fibrosis Therapeutics in Major Developed Market to be Worth $4.0 Billion by 2019

    Vivien Diniz
    Feb. 25, 2016 10:50AM PST
    Biotech Investing

    A report by Radiant Insights indicates that the cystic fibrosis market had a market value of more than USD 695 million in 2012 and is anticipated to rise drastically over the future period in the major 8 developed countries and will surpass USD $4 billion by 2019.

    A report by Radiant Insights indicates that the cystic fibrosis market had a market value of more than USD 695 million in 2012 and is anticipated to rise drastically over the future period in the major 8 developed countries and will surpass USD $4 billion by 2019.
    According to the press release:

    Thus associates to a compounded annual growth rate of more than 30%.

    Click here to view the full press release. 

    cystic fibrosis
    The Conversation (0)
    Go Deeper
    AI Powered
    Senior woman doing exercises alongside closeup of DNA.

    5 US Longevity and Anti-aging Stocks to Watch in 2025

    Microscopic view of stem cells.

    Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025

    Latest News

    RAD receives IND approval from US FDA for Betabart (RV-01)

    Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

    More News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Biotech Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×